Literature DB >> 2165880

Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2.

A Bryant1, N C Calver, E Toubi, A D Webster, J Farrant.   

Abstract

We have classified patients with common variable immunodeficiency (CVI) on the basis of the ability of their B cells to respond to anti-IgM and interleukin (IL)-2 in vitro. Group A had cells unable to secrete IgM or IgG, Group B secreted IgM alone, and Group C secreted both IgM and IgG. A separate small group of patients lacked peripheral B cells. Where Ig secretion was present with anti-IgM and IL-2, EBV increased it, but where it was absent, EBV only induced IgM secretion in two out of eight Group A patients and IgG in one out of five Group B patients. These classifications are related to the sex of the patient and may represent different loci of the block in B-cell differentiation in CVI.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165880     DOI: 10.1016/0090-1229(90)90145-g

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  58 in total

1.  Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

Authors:  M Di Renzo; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

2.  Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS.

Authors:  M Di Renzo; D Serrano; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 3.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

5.  IgH sequences in common variable immune deficiency reveal altered B cell development and selection.

Authors:  Krishna M Roskin; Noa Simchoni; Yi Liu; Ji-Yeun Lee; Katie Seo; Ramona A Hoh; Tho Pham; Joon H Park; David Furman; Cornelia L Dekker; Mark M Davis; Judith A James; Kari C Nadeau; Charlotte Cunningham-Rundles; Scott D Boyd
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

6.  Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency.

Authors:  Megan Dunnigan; Harris Yfantis; Aaron P Rapoport; Keya Hosseinzadeh; Christopher D Gocke; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.199

7.  Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes.

Authors:  J A Rump; D Jakschiess; U Walker; M Schlesier; P von Wussow; H H Peter
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  Effect of 12,13-phorbol dibutyrate and ionomycin on defective B cells in common variable immunodeficiency.

Authors:  A Franz; A Bryant; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

9.  Linkage of autosomal dominant common variable immunodeficiency to chromosome 5p and evidence for locus heterogeneity.

Authors:  D U Braig; A A Schäffer; E Glocker; U Salzer; K Warnatz; H H Peter; B Grimbacher
Journal:  Hum Genet       Date:  2003-02-06       Impact factor: 4.132

10.  The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immunodeficiency.

Authors:  M B Fischer; H M Wolf; H Eggenbauer; V Thon; E Vogel; J Lokaj; J Litzman; J W Mannhalter; M M Eibl
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.